Bharat Biotech's Covaxin offers protection against the Beta and the Delta variants of coronavirus, a joint study by researchers from Pune's National Institute of Virology, the Indian Council of Medical Research (ICMR) and Bharat Biotech has found.
2021-06-09 12:35:27 GMT2021-06-09 20:35:27(Beijing Time) Xinhua English
NEW DELHI, June 9 (Xinhua) A joint study by researchers from Pune s National Institute of Virology, the Indian Council of Medical Research (ICMR) and Bharat Biotech has found that the country s indigenous COVID-19 vaccine, Covaxin, offers protection against the Beta (B.1.351) and the Delta (B.1.617.2) variants, local media reports said Wednesday.
The Delta variant (B.1.617.2) was first found in India and is the dominant strain in the country. The strain caused the deadly second wave in the country. The Beta variant (B.1.351) was first discovered in South Africa.
The study evaluated the neutralisation potential of sera collected from 20 COVID-19 recovered cases and 17 people vaccinated with two doses of Covaxin against Beta and Delta variants and compared it with the prototype D614G variant.
Covaxin provides protection against Beta, Delta variants of Covid-19, claims early study
Covaxin provides protection against Beta, Delta variants of Covid-19, claims early study
According to a study which has not yet been peer-reviewed, Bharat Biotech’s Covaxin in effective against the Beta and Delta variants of Covid-19.
advertisement
UPDATED: June 10, 2021 00:10 IST
A new study has claimed that Covaxin provides protection against Beta and Delta variants of Covid-19. (Photo: AP file)
A study by researchers from the National Institute of Virology in Pune, the Indian Council of Medical Research and vaccine manufacturer Bharat Biotech has found that Covaxin is effective against the Beta and Delta variants of Covid-19.
URL copied
Covishield produces more antibodies with higher seropositivity rate than Covaxin
A preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT) has stated Covishield vaccine produced more antibodies than Covaxin. The study, involving healthcare workers (HCW) who have received both doses of either of the two vaccines, also said seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients as compared to Covaxin after the first dose.
The study is a preprint and has not been peer-reviewed, so should not be used to guide clinical practice.
It said that both vaccines Covishield and Covaxin elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.
India News: The study is titled, Antibody Response after Second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among Health Care Workers in India: Fi